Prescription Medicine Pricing: Our Principles and Perspectives
At Sanofi, we work passionately to help prevent and treat illness and disease, understand and solve healthcare needs of people across the world, and transform the practice of medicine. Our focus spans a number of therapeutic areas in specialty care and general medicines, including immunology, oncology, rare diseases, rare blood disorders, diabetes and cardiovascular diseases, as well as vaccines. Sanofi has a long-standing commitment to promote healthcare systems that make our treatments accessible and affordable to patients in need.
Sanofi understands and shares concerns about the affordability of medicines for patients while also recognizing that we are only one of many stakeholders in the healthcare system. We believe we have a responsibility to be a leader in solving issues of patient access and system viability.
In order to maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. Sanofi is committed to helping address this challenge. For our part, we price our medicines according to their value, while contributing to broader solutions that improve patient outcomes and support affordability within the U.S. healthcare system.
This approach enables affordable access to treatment and continued investment in medical innovation.
Patients seeking further information and assistance may view a list of our prescription products. The “Prescription Products” page provides prescribing information, medication guides, and links to certain brand sites that contain resources on patient assistance. Patients may also view a list of our vaccines products for their prescribing information.
Our Pricing Principles: Advancing Responsible Leadership
Given the growing concerns over rising healthcare costs, we commit to continued transparency in the price of our medicines and to limit any increase in prices in the United States to no more than the projected National Health Expenditure (NHE) growth rate.
